论文部分内容阅读
急性心肌梗塞病人早期使用溶栓药物治疗，迅速溶解阻塞性冠脉血栓，能缩小梗塞范围，保护心功能，降低近期死亡率。我院从１９９１年３月至１９９７年３月应用国产尿激酶（南京大学制药厂）静脉溶栓治疗急性心肌梗塞病人６２例，症状开始至溶栓治疗时间为４．４１±２．６１ｈ（４８例≤６ｈ，１４例＞６ｈ），根据冠脉间接再通指标判断，溶栓治疗再通率为５４．８％（３４／６２）。副作用小，未见脑出血或严重内脏出血。其中，急性心肌梗塞早期（梗塞６ｈ内）大剂量（尿激酶≥１００万ｕ）静脉给药冠脉再通率（３４／４８即７０．８％）比＞６ｈ者、中小剂量高。临床观察证明尿激酶是廉价、安全、有效的溶栓剂
Early use of thrombolytic therapy in patients with acute myocardial infarction, rapid dissolution of obstructive coronary thrombosis, can reduce infarct size, protect cardiac function, reduce the recent mortality. Our hospital from March 1991 to March 1997 application of domestic urokinase (Nanjing University Pharmaceutical Factory) intravenous thrombolytic therapy in 62 patients with acute myocardial infarction, symptoms began to thrombolytic therapy time was 4.41 ± 2.61h (48 Cases ≤ 6h, 14 cases> 6h). According to the index of indirect coronary reperfusion, the recanalization rate of thrombolytic therapy was 54.8% (34/62). Small side effects, no cerebral hemorrhage or severe visceral bleeding. Among them, the early acute myocardial infarction (within 6h) large doses (urokinase ≥ 1000000 u) intravenous administration of coronary recanalization rate (34/48 or 70.8%) than> 6h, high-dose. Clinical observation shows that urokinase is a cheap, safe and effective thrombolytic agent